{
    "relation": [
        [
            "",
            "[A:]Placebo",
            "[B:]Mild",
            "[C.]Moderate"
        ],
        [
            "Description",
            "Placebo to produce no urate elevation",
            "Inosine to produce a mild urate elevation",
            "Inosine to produce a moderate urate elevation"
        ]
    ],
    "pageTitle": "Safety of Urate Elevation in Parkinson's Disease - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00833690?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981856.5/warc/CC-MAIN-20150728002301-00002-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868072643,
    "recordOffset": 868057406,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Placebo Drug: inosine Interventions: Parkinson Disease Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: December 26, 2013 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 [A:]Placebo \u00a0 \u00a0 [B:]Mild \u00a0 \u00a0 [C.]Moderate \u00a0 STARTED \u00a0 \u00a0 25 \u00a0 \u00a0 24 \u00a0 \u00a0 26 \u00a0 COMPLETED \u00a0 \u00a0 21 \u00a0 \u00a0 22 \u00a0 \u00a0 26 \u00a0 NOT COMPLETED \u00a0 \u00a0 4 \u00a0 \u00a0 2 \u00a0 \u00a0 0 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Discontinued study drug \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}